Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Home-Care Program for Bone Marrow Patients

By HospiMedica staff writers
Posted on 08 Nov 2006
A new study shows that patients in need of autologous stem-cell transplantation (ASCT) can undergo this treatment from their own homes, adding a positive impact to the patient's recovery. More...


Researchers from the Institut Clínic of Haematology and Oncology of Hospital Clínic at the University of Barcelona (Barcelona, Spain) followed 178 patients who underwent ASCT for a hematologic malignancy--including such diseases as myeloma, lymphoma, and leukemia--between November 2000 and February 2005. A total of 50 patients were treated with an at-home ASCT program in which prophylactic ceftriaxone and treatment of febrile neutropenia with piperacillin and tazobactam were introduced to minimize the readmission rate. The results were compared with those from 50 other patients with similar characteristics who, despite their appropriateness for the home-care program, were hospitalized conventionally.

The results showed that febrile neutropenia occurred in fewer patients in the at-home group as compared with the hospitalized group, and duration of fever was also shorter in the at-home group. Hospital readmission in the at-home group was required in only four cases (8%). This resulted in a reduction of 18.6 days of hospitalization per patient. Total median hospital charges were approximately half in the at-home group as compared with the in-hospital group. The results were published in the October 20, 2006, issue of the Journal of Clinical Oncology.

"This study has demonstrated that autologous bone marrow transplant can be done ambulatorily in a safe way and with important advantages for the patient. From our start in 2000, one out of three patients is treated at home, a mean of 12-15 patients per year,” said lead author Dr. Francesc Fernández-Avilés.

In order to receive home transplantation, patients needed to meet several requirements, the most important being voluntary participation in the program, having somebody to take care of them 24 hours a day, living relatively close to the hospital, and having the required hygienic conditions at home in order to avoid complications. Appropriate patients underwent preparatory treatment and bone-marrow infusion at the hospital and then returned home, where they were subsequently supervised by a group of nursing staff who monitored the patients daily for fever or other possible complications.



Related Links:
University of Barcelona

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.